Swing Therapeutics Announces The Lancet Publication of Data from Phase 3 Trial of Stanza™ – a Digital Behavioral Therapy for Fibromyalgia Symptoms

Stanza demonstrated significant improvements compared to an active control on virtually all endpoints, including fibromyalgia-related well-being, pain intensity, pain interference, fatigue, and depression. The self-guided, smartphone-based program, which delivers Acceptance and Commitment Therapy, expands access to guideline-directed management of fibromyalgia, with no adverse effects observed. Stanza received FDA De Novo marketing authorization in 2023, as …